[Click eStock] "Hugel, Stock Lightened by Preliminary Examination Win"

On the 12th, Korea Investment & Securities stated that the litigation risk regarding Hugel has eased and expects U.S. sales to be reflected starting from the fourth quarter of this year. The target stock price was raised from the previous 250,000 KRW to 300,000 KRW.

Researcher Wi Haeju from Korea Investment & Securities explained, "The preliminary ITC ruling has been disclosed," adding, "The ITC judge preliminarily ruled that Medytox's case against Hugel did not violate Section 337 of the Tariff Act."

He continued, "According to the ITC decision, the likelihood of Hugel winning the final ruling has increased," and added, "Medytox has stated that it will request a review from the ITC."

He analyzed, "Although the disclosure of the preliminary ruling results poses a burden due to profit-taking volume, there are many positive expectations for Hugel," and "Since the litigation uncertainty has eased, contracts with U.S. partners can be anticipated." Furthermore, he added, "If contracts with U.S. partners are completed and U.S. sales begin to be reflected from the fourth quarter, earnings estimates can be revised upward."

Researcher Wi forecasted, "Although short-term profit-taking volume is a burden, the resolution of uncertainties, profit growth, and corporate value enhancement strategies will continue to drive a positive trend."

This content was produced with the assistance of AI translation services.